Biogen Inc (BIIB)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,906,000 | 1,296,400 | 3,679,700 | 1,608,600 | 4,992,900 |
| Revenue | US$ in thousands | 9,675,900 | 9,835,600 | 10,173,400 | 10,981,700 | 13,444,600 |
| Pretax margin | 19.70% | 13.18% | 36.17% | 14.65% | 37.14% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $1,906,000K ÷ $9,675,900K
= 19.70%
Biogen Inc's pretax margin has exhibited fluctuations over the years based on the provided data. In 2020, the pretax margin was relatively high at 37.14%, indicating that the company was efficient in generating profits before taxes relative to its revenue. However, there was a notable decline in 2021, with the pretax margin dropping to 14.65%, suggesting a decrease in profitability efficiency.
The following year, in 2022, there was a significant improvement as the pretax margin rose to 36.17%, indicating a positive turnaround in the company's profitability performance. Subsequently, in 2023, there was a decline to 13.18%, signaling potential challenges or inefficiencies impacting Biogen's profitability.
By the end of 2024, there was a slight improvement in the pretax margin to 19.70%, although it remained below the levels seen in 2020 and 2022. Overall, these fluctuations in Biogen Inc's pretax margin highlight the company's changing profitability levels and underline the importance of monitoring and addressing factors that can impact financial performance.
Peer comparison
Dec 31, 2024